Nuclear Medicine: Page 21

Novartis suspends shipments of Lu-177 ligand therapy agents

By AuntMinnie.com staff writers

Novartis has temporarily suspended supply of its two therapeutic radiopharmaceuticals based on lutetium-177 (Lu-177) ligands due to "quality issues identified in its manufacturing processes," the company said in a May 5 statement.

May 5, 2022

Use of V/Q scans dropped during COVID-19 pandemic

By Will Morton

Nuclear medicine ventilation/perfusion scintigraphy (V/Q) dropped significantly during the COVID-19 pandemic, as hospitals took up new protocols to reduce the chances of infections, according to an abstract presented at the American Roentgen Ray Society meeting in New Orleans.

May 2, 2022

Sofie to open expanded radiopharm manufacturing center

By AuntMinnie.com staff writers

Sofie plans to expand its existing radiopharmaceutical contract manufacturing facility in Totowa, NJ, from 10,000 square feet to 20,000 square feet.

May 1, 2022

Qsam doses first patient in Cyclosam clinical trial

By AuntMinnie.com staff writers

Qsam Biosciences said the first patient has begun treatment in the company's clinical trial evaluating samarium-153-DOTMP (CycloSam) for the treatment of bone cancer and related diseases.

April 28, 2022

Spectrum rolls out attenuation correction software

By AuntMinnie.com staff writers

Spectrum Dynamics said it has deployed its TruCorr attenuation correction software for its D-SPECT Series digital gamma camera across the U.S., Europe, and Asia.

April 24, 2022

Navidea secures Indian regulatory approval for Lymphoseek

By AuntMinnie.com staff writers

Navidea Biopharmaceuticals has secured regulatory approval from India's Central Drugs Standard Control Organization for its technetium-99m tilmanocept radiopharmaceutical Lymphoseek.

April 17, 2022

Shine appoints two new board members

By AuntMinnie.com staff writers

Medical isotope company Shine Technologies has appointed Holli Ladhani and Janet Wong to the company's board of directors.

April 13, 2022

ITM, MTTI ink lutetium-177 supply deal

By AuntMinnie.com staff writers

ITM Isotope Technologies Munich's subsidiary ITM Medical Isotopes and biopharmaceutical company Molecular Targeting Technologies (MTTI) have signed a supply deal for no-carrier-added lutetium-177.

April 12, 2022

NYSE accepts Navidea bid to comply with stock listing rules

By AuntMinnie.com staff writers

Radiopharmaceutical developer Navidea Biopharmaceuticals said the New York Stock Exchange (NYSE) has accepted its plan to regain compliance with the stock exchange's listing requirements. Navidea now has until July 28, 2023, to regain compliance.

April 12, 2022

Radionetics Oncology taps de Silva as CEO

By AuntMinnie.com staff writers

Pharmaceutical firm Radionetics Oncology has named Dr. Nishan de Silva as CEO and a director of the company's board. De Silva most recently was with AFYX Therapeutics.

April 11, 2022

FDA clears clinical trial for Blue Earth radiopharmaceutical

By AuntMinnie.com staff writers

The U.S. Food and Drug Administration (FDA) has given the go-ahead to Blue Earth Therapeutics to conduct a clinical study of its radiopharmaceutical labeled with lutetium-177 for treatment of metastatic, castrate-resistant prostate cancer.

April 11, 2022

German scientists develop method for less uranium waste

By AuntMinnie.com staff writers

Technical University of Munich scientists have developed a new processing method for molybdenum-99 (Mo-99) that results in significantly less waste from low-enriched uranium targets.

March 30, 2022

Previous Page

Page 21 of 438

Next Page